Active surveillance under-used (back in 2010-2011)

A new research letter just published in JAMA Internal Medicine suggests that only about 12 percent or less of the men who are good candidates for active surveillance are actually being managed in that manner. But, … READ MORE …

Active surveillance, upgrading on repeat biopsy, and consequent management

In February this year we commented on an article that argued in favor of active surveillance as an appropriate initial management strategy for “favorable” intermediate-risk prostate cancer. … READ MORE …

Tokai initiates trial of galeterone in men with AR-V7-positive mCRPC

According to information released earlier today by Tokai Pharmaceuticals, the company has started to enroll patients with AR-V7-positive, metastatic, castration-resistant prostate cancer (mCRPC) into a randomized Phase III clinical trial of treatment with galeterone. … READ MORE …

Should all patients starting on ADT be on a statin too?

A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …

Does diagnosis/treatment for prostate cancer increase risk for colorectal cancer too?

A newly published study in the journal of Cancer Control has again suggested the possibility that men treated for prostate cancer may be at elevated risk for a secondary diagnosis of colorectal cancer by comparison with similar men never diagnosed with prostate cancer. … READ MORE …

Assessing the “value” of new drugs in the treatment of [prostate] cancer

Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …

Astellas, Medivation initiate TRUMPET registry study

Many patients newly diagnosed with castration-resistant prostate cancer (CRPC) may be interested in participating in a new registry study known as the TRUMPET study, which has just started to enroll patients and is sponsored by Astellas and Medivation (the developers and marketers of enzalutamide/Xtandi). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,320 other followers